Xtant Medical Expects FY2024 Sales Of $112M-$116M Versus Consensus Of $115.95M
$XTNT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Xtant Medical Expects FY2024 Sales Of $112M-$116M Versus Consensus Of $115.95M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2023 | $2.00 | Buy | BTIG Research |
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi
BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference:Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 MeetingsFor more information, please visit: https://www.meetmax.com/sched/event_110237/conference_home.html?bank_access=0&event_id=110237About Xtant Medical Holdings, Inc.Xtant Medical's mission of honoring the gift of donation so that our
BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:
BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi
BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.Conference Details:Conference Date: Friday, August 9, 2024Conference Time: 9:00 AM ETConference dial-in: 888-999-3182International dial-in: 848-280-6330Pas
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)
8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
EFFECT - Xtant Medical Holdings, Inc. (0001453593) (Filer)
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va
BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million. Bionomics (NASDAQ:BNOX) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million. Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million. Xtant Medical Hldgs (AMEX:XTNT) stock moved upwards by 20.97% to $0.9. The market value of their outstandi
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and raises the price target from $2 to $3.
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 200 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $27.873 million which beat the analyst consensus estimate of $25.750 million by 8.24 percent. This is a 55.34 percent increase over sales of $17.943 million the same period last year.